Loading clinical trials...
Loading clinical trials...
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients: A Randomized, Multicenter, Double Blind, Placebo-Controlled Trial (CTOT-47)
Conditions
Interventions
Belumosudil
Placebo for Belumosudil
Locations
12
United States
University of California, Los Angeles (Site #: 71123)
Los Angeles, California, United States
Stanford University (Site #: 71141)
Palo Alto, California, United States
Johns Hopkins (Site #: 71119)
Baltimore, Maryland, United States
University of Minnesota (Site 71151)
Minneapolis, Minnesota, United States
Washington University (Site #: 71157)
St Louis, Missouri, United States
NYU Langone Health (Site #: 71177)
New York, New York, United States
Start Date
March 12, 2025
Primary Completion Date
May 30, 2027
Completion Date
June 30, 2027
Last Updated
April 17, 2026
NCT07046910
NCT05837663
NCT07235683
NCT04118660
NCT06990711
NCT07291258
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions